New insider activity at United Therapeutics ( (UTHR) ) has taken place on May 13, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Director Nilda Mesa of United Therapeutics has recently sold 258 shares of the company’s stock in a transaction valued at $150,137, signaling a notable insider move that may draw attention from investors tracking executive trading activity.
Recent Updates on UTHR stock
United Therapeutics shares reacted to a busy news cycle as the company deepened its pulmonary disease pipeline and drew mixed analyst responses. A collaboration with Varda Space to use microgravity for advanced pulmonary formulations and plans to showcase multiple positive treprostinil and ralinepag data sets at a major thoracic conference underscored long‑term innovation.
Wells Fargo raised its outlook, citing greater confidence in ralinepag DPI strengthening the firm’s competitive position in pulmonary indications and expectations for a strong idiopathic pulmonary fibrosis launch offsetting potential Tyvaso softness. In contrast, Morgan Stanley made a minor downward adjustment to its valuation framework while maintaining a neutral stance, reflecting a more cautious view despite the robust clinical and strategic updates.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
The score is driven primarily by strong financial quality (high margins, strong cash generation, and a debt-free balance sheet) and a positive earnings-call backdrop with significant clinical wins and clear regulatory/launch milestones. Offsetting factors are the sharp TTM revenue decline and only mixed near-term technical momentum; valuation appears reasonable but not clearly cheap given near-term top-line uncertainty.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
YTD Price Performance: 19.39%
Average Trading Volume: 550,042
Technical Sentiment Signal: Buy
Current Market Cap: $24.69B